Sanofi's big dermatology hope fails in phase III

One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.

Photo: Dado Ruvic/REUTERS / X02714

As things appear at the moment, Sanofi hasn't achieved its ambitions with drug rilzabrutinib that management had otherwise hoped when the French pharmaceutical company acquired the compound via its acquisition of Prinicipia Biopharma in 2020.

In any case, rilzabrutinib has showed itself to be a real fiasco within the field of dermatology. Here, the medication failed to pass its phase III trial as a treatment for two variants of the rare autoimmune skin disease pemfigus vulgaris and pemfigus foliaceus. The condition is characterized by blisters on skin and mucus membranes, sometimes leading to death among patients with compromised immune systems.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs